Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography

Journal of Nephrology

Volumn 25, Issue 5, 2012, Pages 794-801

  Matsumoto, Mayumi ^a   Io, Hiroaki ^a   Furukawa, Masako ^a   Okumura, Kozue ^a   Masuda, Atsumi ^a   Seto, Takuya ^a   Takagi, Miyuki ^a   Sato, Michiko ^a   Nagahama, Lili ^a   Omote, Keisuke ^a   Hisada, Atsuko ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anemia; Blood pressure; Chronic kidney disease; Echocardiography; Left ventricular hypertrophy; Left ventricular mass index

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; JAPAN; MALE; PHYSICAL PARAMETERS; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANEMIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84867017660     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000066     Document Type: Article

References (32)

1. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004;65(2):626-633.
2. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4(Suppl.1):S79-S91.
3. Io H, Matsumoto M, Okumura K, et al. Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial. 2011;24(3):349-354.
4. Matsuo S, Imai E, Horio Y, et al. Collaborators developing the Japanese equation for estimated GFR. Am J Kidney Dis. 2009;53:982-992.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(Suppl 1):S1-S266.
6. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20(5):1251-1260.
7. Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography's Guideline and Standard Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-1463.
8. Tripepi G, Benedetto FA, Mallamaci F, Tripepi R, Malatino L, Zoccali C. Left atrial volume monitoring and cardiovascular risk in patients with end-stage renal disease: a prospective cohort study. J Am Soc Nephrol. 2007;18(4):1316-1322.
9. Furukawa M, Io H, Tanimoto M, Hagiwara S, Horikoshi S, Tomino Y. Predictive factors associated with the period of time before initiation of hemodialysis in CKD stages 4 and 5. Nephron Clin Pract. 2011;117(4):c341-c347.
10. Io H, Ro Y, Sekiguchi Y, et al. Cardiac function and structure in longitudinal analysis of echocardiography in peritoneal dialysis patients. Perit Dial Int. 2010;30(3):353-361.
11. Leonardis D, Basta G, Mallamaci F, et al. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2011 Apr 4. [Epub ahead of print]
12. Stancanelli B, Makatino LS, Cataliotti A, et al. Soluble eselectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients. Nephron Clin Pract. 2010;114:c74-c80.
13. Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophyis associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertensions Res. 2004;27:47-52.
14. Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J. 2006;82:357-362.
15. Palmieri V, Bella JN, Roman MJ, et al. Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens. 2003;21:781-787.
16. US Renal Data System. USRDS 2002 Annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
17. Spoto B, Testa A, Parlongo RM, et al. Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. Nephrol Dial Transplant. 2011 May 19. [Epub ahead of print]
18. Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology. 2009;24:17-25.
19. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfal in human blood vessels. Kidney Int. 2003;63:1003-1011.
20. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
21. Neves KR, Graciolli FG, Dos Reis LM, Pasqualucci CA, Moysés RM, Jorgett V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004;66:2237-2244.
22. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int. 2005;67 (Suppl.95):S37-S42.
23. Testa A, Mallamaci F, Benedetto FA, et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res. 2010;25:313-319.
24. Locatelli F, Bommer J, London GM, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant. 2001;16: 459-468.
25. London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001;16 (Suppl 2):S3-S6.
26. Guyton AC, Coleman TG, Wilcox CS. Quantitative analysis of the pathophysiology of hypertension. J Am Soc Nephrol.1999;10:2248-2249.
27. Charra B, Calemard E, Laurent G. Importance of treatment time and blood pressure control in achieving long-term sur-vival on dialysis. Am J Nephrol. 1996;16:35-44.
28. Go AS, Chertow GM, Fan D, MuCulloch CE, Hsu CY. Chronic kidney disease and risks of death, cardiovascular events,and hospitalization. N Engl J Med. 2003;351:1296-1305.
29. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738-750.
30. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol. 2003;14:S173-S177.
31. Galderisi M, Petrocelli A, Alfieri A, Garofalo M, de Divitiis O. Impact of ambulatory blood pressure on left ventricular diastolic dysfunction in uncomplicated arterial systemic hypertension. Am J Cardiol. 1996;77:597-601.
32. Aqabiti RE, Muiesan ML, Salvetti M. New approaches to the assessment of left ventricular hypertrophy. Ther Adv Cardiovasc Dis. 2007;1:119-128.